Physician profile
Fan Li
NPI 1659368330
$1,333.31
in general payments reported to CMS, 2019-2025
18 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.72 · 2022: $235 · 2023: $534 · 2024: $251 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $334.62 | 2021-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $229.34 | 2022-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $123.78 | 2023 | Xarelto |
| Exact Sciences Corporation | $123.66 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $78.41 | 2023 | Dexcom G7 Gss (161) |
| Mylan Specialty L.P. | $68.52 | 2022-2023 | Yupelri |
| Glaxosmithkline, LLC. | $64.88 | 2022-2024 | Arexvy |
| Otsuka America Pharmaceutical, INC. | $48.12 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.50 | 2023-2024 | |
| Novo Nordisk INC | $39.33 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $31.68 | 2022-2023 | Zepbound, Jardiance |
| Astellas Pharma US INC | $28.18 | 2023-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $25.31 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $23.16 | 2023 | Trintellix |
| Esperion Therapeutics, INC. | $22.29 | 2023 | Nexletol |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.17 | 2024 | Capvaxive |
| Abbvie INC. | $16.08 | 2022 | |
| Amgen INC. | $14.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fan Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.